Search

Imperial College London's technology commercialisation company is betting on a spin-out company, deltaDOT, to speed detection and decrease costs of finding new proteins for drug discovery.

Avidex is teaming up with diabetes specialists at King’s College London to work on a new approach to treating the Type I form of the disease.

Europe looks increasingly likely to follow America’s lead and require drug companies to test their products in children. But Europe's pharma lack the resources to carry out drug trials in children — so industry and patients will have to rely on the skills developed in academic centres.

A new life-science fund said it raised €240.3 million – and promptly announced its first two investments.

Nemerix, a semiconductor company spun out from the Swiss Federal Institute of Technology in Zurich, has closed a €25 million series B financing round.

Oslo-based anticancer company Algeta has closed a series A financing round totaling €23 million.

Mary Lisbeth D'Amico's first fortnightly funding column reveals how coming out on top in a start-up talent show does not guarantee funding.

One of Europe’s biggest research organisations, Fraunhofer Gesellschaft in Germany, is pushing to close its first venture fund to finance spin-off companies from the institute.

Take care: not all spin-outs end in fame and glory. The path from academia to industry is strewn with pitfalls…

IBM’s savvy move to share 500 patents may spark innovation in computer software and in how companies handle IP.

Technology from one of France’s Grandes Écoles is going towards developing an easy-to-program home robot – with a common touch

No, it has nothing to do with government PR. It's an exotic thing that you can do with electrons.

Not everyone can produce a Google, Stanford's way of doing business is making other universities look with interest at the revenue possibilities of equity deals.

Once upon a time, there were great businesses with massive central labs that did both product development and basic research. Today, most corporate labs have refocused on applied research. They do not know what they are missing.

Acquisition gives Roche access to antibody-boosting technology - and possible anti-cancer treatments in the pipeline

How a Swiss university spin-off got to exit in six years - Interview with Joël Jean-Mairet, Chief Executive Officer and Joint Founder, GlycArt.